KRW 15.5 Billion in Funding: The Next Chapter for RAWGA

In May, RAWGA completed a KRW 15.5 billion Series B funding round led by KB Investment. More than a financial milestone, this investment marks a new starting point for strengthening our production foundation and expanding our technology into global business opportunities.
With this investment, RAWGA is accelerating the expansion of its production foundation, including the construction of a new manufacturing facility in Sejong. Once completed, the facility is expected to increase our production capacity and provide infrastructure designed to support GMP-compliant operations, enabling us to respond to a broader portfolio of premium functional ingredients and products.
Our next stage of growth goes beyond production expansion.
Building on our plant-based collagen business, proprietary IP, and natural peptide technologies, RAWGA is expanding its functional ingredient pipeline across areas including skin health, joint health, muscle health, and healthy aging. We also aim to combine AI technology with clinical and protocol data to develop more precise functional ingredient solutions and strengthen our technology-driven competitiveness in the global market.
This investment is not a destination. It is the beginning of our next step—connecting technology with production and global commercialization.